The Beijing Municipal Science & Technology Commission, in conjunction with the Administrative Commission of Zhongguancun Science Park, has unveiled the “Beijing Action Plan for Accelerating Collaborative Innovation in Medicine and Health (2024-2026)”. The plan is designed to cement Beijing’s position as a global hub for cell and gene therapy (CGT) innovation. The public has the opportunity to provide feedback on the document until 5 pm on October 15th.<\/p>\n\n\n\n
Overall Objectives:<\/strong><\/p>\n\n\n\n The action plan sets ambitious targets for the city by 2026, including the addition of over 15 clinical trial approvals and the filing for marketing approval of more than 5 innovative varieties. The initiative aims to cultivate over 20 cutting-edge technology enterprises in the CGT field, with at least 3 companies going public and the introduction of 1-2 multinational corporations. The plan envisions the establishment of a translation carrier platform and a common technology service platform to support the industry’s urgent needs, offering comprehensive services from technology R&D to inspection and testing for no fewer than 20 varieties. This will lay the groundwork for a globally influential CGT industry cluster.<\/p>\n\n\n\n